Karin Conde-Knape

Karin began their pharmaceutical career at Johnson and Johnson in September of 2013 as Vice President for Cardiovascular and Metabolism. In this role, Karin was responsible for identifying, establishing, and managing external scientific opportunities for early research through clinical POCs in the area of cardiovascular and metabolism.

In April of 2010, Karin took on the role of Acting Head of Discovery for Roche. In this role, they were responsible for all discovery efforts in the cardiovascular and metabolism DTA. Karin was with Roche for just over three years before moving on to their current position at Novo Nordisk.

Karin is currently Senior Vice President of Global Drug Discovery at Novo Nordisk. In this role, they are responsible for leading the global drug discovery organization and strategies across all Novo Nordisk R&D sites.

Karin Conde-Knape is a post-doctoral researcher in the field of lipids and lipoproteins at Columbia University Vagelos College of Physicians and Surgeons. Karin holds a PhD from the University of Connecticut.

Karin Conde-Knape reports to Marcus Schindler, EVP for Research and Early Development & Chief Scientific Officer. A direct report to Karin Conde-Knape is and Mads Tang-Christensen - CVP, Therapeutic Area Head Global Obesity & Liver Disease Research. They are on a team with Rasmus Rabøl - Corporate Vice President, Translational Science and Medicine, Anette Spahn Klausen - EVP Communication Partner, and Jesper Bøving - Senior Vice President CMC.